Amgen · 1 month ago
Complex Biologics -Grad Intern (Summer 2026)
Amgen is a leading biotechnology company focused on serving patients with serious illnesses. They are seeking a motivated summer intern in the Complex Biologics Department to explore new technologies and contribute to the development of antibody drug conjugates.
BiotechnologyHealth CareManufacturingPharmaceutical
Responsibilities
Evaluate novel conjugation methods
Design, synthesize, and evaluate novel linkers for antibody drug conjugates
Synthesize and evaluate antibody drug conjugates using the novel linkers
Review, analyze, and interpret scientific data and results; provide regular updates and present project results internally
Qualification
Required
18 years or older
Graduated with a bachelor's degree from an accredited college or university
Currently enrolled in an MBA program for an MBA internship OR a Master's program for a Master's internship OR a PharmD program for a PharmD internship OR Ph.D. for a PhD internship from an accredited college or university and completion of the first year of MBA OR Master's OR Pharm D OR Ph.D. program before the internship starts
Enrolled in an accredited college or university following the potential internship
Must not be employed at the time the internship starts
Student must be located in the United States for the duration of the internship
Preferred
Proficient skills in synthetic chemistry and knowledge of state-of-the-art protein biochemistry techniques
Clear understanding of structural determination using NMR and MS techniques and proficient with a range of chromatography methods (e.g. HPLC, RP HPLC, ion exchange, size exclusion chromatography)
Demonstration of good lab practices, with particular attention to safety
Strong written and verbal communication skills
Ability to work comfortably within a team of scientists and engineers with diverse technical and cultural backgrounds
Company
Amgen
Amgen is a biotechnology company that develops and manufactures human therapeutics for various illnesses and diseases.
Funding
Current Stage
Public CompanyTotal Funding
$28.5B2022-12-12Post Ipo Debt· $28.5B
1983-06-17IPO
Leadership Team
Recent News
2026-01-13
Genetic Engineering News
2026-01-12
Company data provided by crunchbase